nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—Triamcinolone—psoriasis	0.191	0.424	CbGbCtD
Clodronate—PTGS2—Betamethasone—psoriasis	0.164	0.364	CbGbCtD
Clodronate—PTGS2—Dexamethasone—psoriasis	0.0954	0.212	CbGbCtD
Clodronate—PTGS2—skeletal joint—psoriasis	0.0126	0.173	CbGeAlD
Clodronate—SLC25A6—skin of body—psoriasis	0.0116	0.16	CbGeAlD
Clodronate—SLC25A5—Electron Transport Chain—NDUFA5—psoriasis	0.0103	0.128	CbGpPWpGaD
Clodronate—SLC25A5—skin of body—psoriasis	0.0101	0.139	CbGeAlD
Clodronate—PTGS2—synovial membrane of synovial joint—psoriasis	0.0096	0.132	CbGeAlD
Clodronate—SLC25A6—Electron Transport Chain—NDUFA5—psoriasis	0.00863	0.107	CbGpPWpGaD
Clodronate—SLC25A5—tendon—psoriasis	0.00771	0.106	CbGeAlD
Clodronate—SLC25A4—tendon—psoriasis	0.00723	0.0991	CbGeAlD
Clodronate—SLC25A4—Electron Transport Chain—NDUFA5—psoriasis	0.00674	0.0836	CbGpPWpGaD
Clodronate—PTGS2—skin epidermis—psoriasis	0.00616	0.0844	CbGeAlD
Clodronate—PTGS2—endothelium—psoriasis	0.00447	0.0613	CbGeAlD
Clodronate—SLC25A4—Vitamin A—Acitretin—psoriasis	0.00422	0.227	CbGdCrCtD
Clodronate—SLC25A4—Tretinoin—Acitretin—psoriasis	0.00295	0.158	CbGdCrCtD
Clodronate—SLC25A4—Alitretinoin—Acitretin—psoriasis	0.00295	0.158	CbGdCrCtD
Clodronate—SLC25A4—Isotretinoin—Acitretin—psoriasis	0.00295	0.158	CbGdCrCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00236	0.0293	CbGpPWpGaD
Clodronate—PTGS2—skin of body—psoriasis	0.00191	0.0262	CbGeAlD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.00186	0.0231	CbGpPWpGaD
Clodronate—SLC25A5—Host Interactions of HIV factors—HLA-A—psoriasis	0.00186	0.0231	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—HLA-A—psoriasis	0.00156	0.0194	CbGpPWpGaD
Clodronate—PTGS2—tendon—psoriasis	0.00145	0.0199	CbGeAlD
Clodronate—SLC25A4—Host Interactions of HIV factors—HLA-A—psoriasis	0.00122	0.0151	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—HLA-A—psoriasis	0.00121	0.015	CbGpPWpGaD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD4—psoriasis	0.0012	0.0149	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NDUFA5—psoriasis	0.00117	0.0145	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.00117	0.0145	CbGpPWpGaD
Clodronate—Anorexia—Calcitriol—psoriasis	0.00112	0.00298	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.00109	0.0136	CbGpPWpGaD
Clodronate—Pneumonia—Mycophenolic acid—psoriasis	0.00109	0.00288	CcSEcCtD
Clodronate—Rash—Beclomethasone—psoriasis	0.00106	0.00282	CcSEcCtD
Clodronate—Dermatitis—Beclomethasone—psoriasis	0.00106	0.00282	CcSEcCtD
Clodronate—Blood creatinine increased—Cyclosporine—psoriasis	0.00106	0.00282	CcSEcCtD
Clodronate—Renal failure—Mycophenolic acid—psoriasis	0.00106	0.00281	CcSEcCtD
Clodronate—Rash—Fluocinonide—psoriasis	0.00106	0.0028	CcSEcCtD
Clodronate—Dermatitis—Fluocinonide—psoriasis	0.00105	0.0028	CcSEcCtD
Clodronate—Urticaria—Methoxsalen—psoriasis	0.00105	0.00278	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.00104	0.013	CbGpPWpGaD
Clodronate—Infection—Acitretin—psoriasis	0.00104	0.00276	CcSEcCtD
Clodronate—Infection—Fluocinolone Acetonide—psoriasis	0.00104	0.00275	CcSEcCtD
Clodronate—Blood creatinine increased—Mycophenolate mofetil—psoriasis	0.00104	0.00275	CcSEcCtD
Clodronate—Abdominal pain upper—Cyclosporine—psoriasis	0.00104	0.00275	CcSEcCtD
Clodronate—Cardiac failure—Hydrocortisone—psoriasis	0.00103	0.00274	CcSEcCtD
Clodronate—Dehydration—Mycophenolate mofetil—psoriasis	0.00103	0.00273	CcSEcCtD
Clodronate—Decreased appetite—Calcitriol—psoriasis	0.00102	0.00271	CcSEcCtD
Clodronate—Skin disorder—Acitretin—psoriasis	0.00102	0.0027	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—HLA-A—psoriasis	0.00101	0.0126	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD4—psoriasis	0.00101	0.0125	CbGpPWpGaD
Clodronate—Nausea—Beclomethasone—psoriasis	0.001	0.00266	CcSEcCtD
Clodronate—Anorexia—Acitretin—psoriasis	0.000998	0.00265	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CYP2S1—psoriasis	0.000994	0.0123	CbGpPWpGaD
Clodronate—Extravasation—Methotrexate—psoriasis	0.000989	0.00262	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—psoriasis	0.000982	0.0026	CcSEcCtD
Clodronate—Dysphagia—Cyclosporine—psoriasis	0.00098	0.0026	CcSEcCtD
Clodronate—SLC25A6—Metabolism—NDUFA5—psoriasis	0.000979	0.0122	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000975	0.00259	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—REN—psoriasis	0.000973	0.0121	CbGpPWpGaD
Clodronate—Protein urine present—Methotrexate—psoriasis	0.000969	0.00257	CcSEcCtD
Clodronate—Bronchospasm—Cyclosporine—psoriasis	0.000964	0.00256	CcSEcCtD
Clodronate—Pharyngitis—Mycophenolic acid—psoriasis	0.000962	0.00255	CcSEcCtD
Clodronate—Urinary tract disorder—Mycophenolic acid—psoriasis	0.000957	0.00254	CcSEcCtD
Clodronate—Dysphagia—Mycophenolate mofetil—psoriasis	0.000956	0.00253	CcSEcCtD
Clodronate—Connective tissue disorder—Mycophenolic acid—psoriasis	0.000953	0.00253	CcSEcCtD
Clodronate—Urethral disorder—Mycophenolic acid—psoriasis	0.00095	0.00252	CcSEcCtD
Clodronate—Oliguria—Methotrexate—psoriasis	0.000936	0.00248	CcSEcCtD
Clodronate—Urticaria—Calcitriol—psoriasis	0.000935	0.00248	CcSEcCtD
Clodronate—Pruritus—Methoxsalen—psoriasis	0.000935	0.00248	CcSEcCtD
Clodronate—Anaemia—Hydroxyurea—psoriasis	0.000931	0.00247	CcSEcCtD
Clodronate—Abdominal pain—Calcitriol—psoriasis	0.000931	0.00247	CcSEcCtD
Clodronate—Dyspepsia—Acitretin—psoriasis	0.000922	0.00244	CcSEcCtD
Clodronate—Abdominal pain upper—Hydrocortisone—psoriasis	0.00092	0.00244	CcSEcCtD
Clodronate—Decreased appetite—Acitretin—psoriasis	0.00091	0.00241	CcSEcCtD
Clodronate—Gastrointestinal disorder—Acitretin—psoriasis	0.000904	0.0024	CcSEcCtD
Clodronate—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000902	0.00239	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000889	0.00236	CcSEcCtD
Clodronate—Cardiac failure—Dexamethasone—psoriasis	0.000882	0.00234	CcSEcCtD
Clodronate—Cardiac failure—Betamethasone—psoriasis	0.000882	0.00234	CcSEcCtD
Clodronate—Pneumonia—Cyclosporine—psoriasis	0.000879	0.00233	CcSEcCtD
Clodronate—Mediastinal disorder—Mycophenolic acid—psoriasis	0.000874	0.00232	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000872	0.0468	CbGdCrCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000862	0.0107	CbGpPWpGaD
Clodronate—Renal failure—Cyclosporine—psoriasis	0.000859	0.00228	CcSEcCtD
Clodronate—Pneumonia—Mycophenolate mofetil—psoriasis	0.000857	0.00227	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000852	0.00226	CcSEcCtD
Clodronate—Renal failure—Mycophenolate mofetil—psoriasis	0.000838	0.00222	CcSEcCtD
Clodronate—Pruritus—Calcitriol—psoriasis	0.000833	0.00221	CcSEcCtD
Clodronate—Rash—Methoxsalen—psoriasis	0.000833	0.00221	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CYP2S1—psoriasis	0.000833	0.0103	CbGpPWpGaD
Clodronate—Dermatitis—Methoxsalen—psoriasis	0.000832	0.00221	CcSEcCtD
Clodronate—Urticaria—Acitretin—psoriasis	0.000832	0.00221	CcSEcCtD
Clodronate—Abdominal pain—Acitretin—psoriasis	0.000828	0.0022	CcSEcCtD
Clodronate—Infection—Hydroxyurea—psoriasis	0.000817	0.00217	CcSEcCtD
Clodronate—Diarrhoea—Calcitriol—psoriasis	0.000806	0.00214	CcSEcCtD
Clodronate—Skin disorder—Hydroxyurea—psoriasis	0.000799	0.00212	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—HLA-A—psoriasis	0.000792	0.00983	CbGpPWpGaD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD4—psoriasis	0.000785	0.00975	CbGpPWpGaD
Clodronate—Nausea—Methoxsalen—psoriasis	0.000785	0.00208	CcSEcCtD
Clodronate—Anorexia—Hydroxyurea—psoriasis	0.000784	0.00208	CcSEcCtD
Clodronate—SLC25A5—HIV Infection—CD4—psoriasis	0.00078	0.00968	CbGpPWpGaD
Clodronate—Anaemia—Mycophenolic acid—psoriasis	0.00078	0.00207	CcSEcCtD
Clodronate—Pharyngitis—Cyclosporine—psoriasis	0.000778	0.00206	CcSEcCtD
Clodronate—Urinary tract disorder—Cyclosporine—psoriasis	0.000774	0.00205	CcSEcCtD
Clodronate—Connective tissue disorder—Cyclosporine—psoriasis	0.000771	0.00204	CcSEcCtD
Clodronate—Urethral disorder—Cyclosporine—psoriasis	0.000769	0.00204	CcSEcCtD
Clodronate—Cardiac failure—Prednisone—psoriasis	0.000768	0.00204	CcSEcCtD
Clodronate—SLC25A4—Metabolism—NDUFA5—psoriasis	0.000765	0.00949	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—REN—psoriasis	0.000759	0.00942	CbGpPWpGaD
Clodronate—Pharyngitis—Mycophenolate mofetil—psoriasis	0.000759	0.00201	CcSEcCtD
Clodronate—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000756	0.002	CcSEcCtD
Clodronate—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000752	0.00199	CcSEcCtD
Clodronate—Urethral disorder—Mycophenolate mofetil—psoriasis	0.00075	0.00199	CcSEcCtD
Clodronate—Vomiting—Calcitriol—psoriasis	0.000749	0.00198	CcSEcCtD
Clodronate—Rash—Calcitriol—psoriasis	0.000742	0.00197	CcSEcCtD
Clodronate—Dermatitis—Calcitriol—psoriasis	0.000742	0.00197	CcSEcCtD
Clodronate—Pruritus—Acitretin—psoriasis	0.000741	0.00196	CcSEcCtD
Clodronate—Pruritus—Fluocinolone Acetonide—psoriasis	0.000739	0.00196	CcSEcCtD
Clodronate—Dyspnoea—Hydroxyurea—psoriasis	0.000733	0.00194	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000724	0.00899	CbGpPWpGaD
Clodronate—Dyspepsia—Hydroxyurea—psoriasis	0.000724	0.00192	CcSEcCtD
Clodronate—Diarrhoea—Acitretin—psoriasis	0.000717	0.0019	CcSEcCtD
Clodronate—Decreased appetite—Hydroxyurea—psoriasis	0.000715	0.0019	CcSEcCtD
Clodronate—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000715	0.00189	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000713	0.00189	CcSEcCtD
Clodronate—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00071	0.00188	CcSEcCtD
Clodronate—Mediastinal disorder—Cyclosporine—psoriasis	0.000707	0.00187	CcSEcCtD
Clodronate—Nausea—Calcitriol—psoriasis	0.000699	0.00185	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000699	0.0375	CbGdCrCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000697	0.00865	CbGpPWpGaD
Clodronate—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000689	0.00183	CcSEcCtD
Clodronate—Connective tissue disorder—Hydrocortisone—psoriasis	0.000685	0.00182	CcSEcCtD
Clodronate—Infection—Mycophenolic acid—psoriasis	0.000684	0.00181	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000679	0.00843	CbGpPWpGaD
Clodronate—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000679	0.0365	CbGdCrCtD
Clodronate—Renal failure acute—Methotrexate—psoriasis	0.000679	0.0018	CcSEcCtD
Clodronate—Skin disorder—Mycophenolic acid—psoriasis	0.000669	0.00177	CcSEcCtD
Clodronate—Vomiting—Acitretin—psoriasis	0.000666	0.00177	CcSEcCtD
Clodronate—Vomiting—Fluocinolone Acetonide—psoriasis	0.000664	0.00176	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Prednisone—psoriasis	0.000661	0.00175	CcSEcCtD
Clodronate—Rash—Acitretin—psoriasis	0.00066	0.00175	CcSEcCtD
Clodronate—Dermatitis—Acitretin—psoriasis	0.00066	0.00175	CcSEcCtD
Clodronate—Rash—Fluocinolone Acetonide—psoriasis	0.000659	0.00175	CcSEcCtD
Clodronate—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000658	0.00174	CcSEcCtD
Clodronate—Anorexia—Mycophenolic acid—psoriasis	0.000656	0.00174	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CD4—psoriasis	0.000654	0.00811	CbGpPWpGaD
Clodronate—Pharyngitis—Triamcinolone—psoriasis	0.000651	0.00173	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CYP2S1—psoriasis	0.00065	0.00807	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000637	0.00791	CbGpPWpGaD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000633	0.00785	CbGpPWpGaD
Clodronate—Anaemia—Cyclosporine—psoriasis	0.000631	0.00167	CcSEcCtD
Clodronate—Angioedema—Cyclosporine—psoriasis	0.000624	0.00165	CcSEcCtD
Clodronate—Nausea—Acitretin—psoriasis	0.000622	0.00165	CcSEcCtD
Clodronate—Nausea—Fluocinolone Acetonide—psoriasis	0.00062	0.00164	CcSEcCtD
Clodronate—Anaemia—Mycophenolate mofetil—psoriasis	0.000616	0.00163	CcSEcCtD
Clodronate—Dyspnoea—Mycophenolic acid—psoriasis	0.000614	0.00163	CcSEcCtD
Clodronate—Angioedema—Mycophenolate mofetil—psoriasis	0.000609	0.00161	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—ACE—psoriasis	0.000607	0.00753	CbGpPWpGaD
Clodronate—Dyspepsia—Mycophenolic acid—psoriasis	0.000606	0.00161	CcSEcCtD
Clodronate—Decreased appetite—Mycophenolic acid—psoriasis	0.000599	0.00159	CcSEcCtD
Clodronate—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000595	0.00158	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—JUN—psoriasis	0.000593	0.00735	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000584	0.00725	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000577	0.00153	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.00057	0.00708	CbGpPWpGaD
Clodronate—Angioedema—Prednisolone—psoriasis	0.000568	0.00151	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000563	0.00149	CcSEcCtD
Clodronate—Diarrhoea—Hydroxyurea—psoriasis	0.000563	0.00149	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000557	0.00691	CbGpPWpGaD
Clodronate—Angioedema—Hydrocortisone—psoriasis	0.000554	0.00147	CcSEcCtD
Clodronate—Infection—Cyclosporine—psoriasis	0.000554	0.00147	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000552	0.00684	CbGpPWpGaD
Clodronate—Abdominal pain—Mycophenolic acid—psoriasis	0.000544	0.00144	CcSEcCtD
Clodronate—Skin disorder—Cyclosporine—psoriasis	0.000541	0.00143	CcSEcCtD
Clodronate—Infection—Mycophenolate mofetil—psoriasis	0.00054	0.00143	CcSEcCtD
Clodronate—Anorexia—Cyclosporine—psoriasis	0.000531	0.00141	CcSEcCtD
Clodronate—Skin disorder—Mycophenolate mofetil—psoriasis	0.000528	0.0014	CcSEcCtD
Clodronate—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000526	0.0283	CbGdCrCtD
Clodronate—Vomiting—Hydroxyurea—psoriasis	0.000523	0.00139	CcSEcCtD
Clodronate—Angioedema—Triamcinolone—psoriasis	0.000522	0.00138	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000521	0.00646	CbGpPWpGaD
Clodronate—Rash—Hydroxyurea—psoriasis	0.000518	0.00137	CcSEcCtD
Clodronate—Anorexia—Mycophenolate mofetil—psoriasis	0.000518	0.00137	CcSEcCtD
Clodronate—Dermatitis—Hydroxyurea—psoriasis	0.000518	0.00137	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000518	0.00642	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000513	0.00136	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—CD4—psoriasis	0.00051	0.00633	CbGpPWpGaD
Clodronate—Connective tissue disorder—Prednisone—psoriasis	0.00051	0.00135	CcSEcCtD
Clodronate—Dyspnoea—Cyclosporine—psoriasis	0.000497	0.00132	CcSEcCtD
Clodronate—Infection—Hydrocortisone—psoriasis	0.000492	0.0013	CcSEcCtD
Clodronate—Dyspepsia—Cyclosporine—psoriasis	0.00049	0.0013	CcSEcCtD
Clodronate—Nausea—Hydroxyurea—psoriasis	0.000488	0.0013	CcSEcCtD
Clodronate—Pruritus—Mycophenolic acid—psoriasis	0.000487	0.00129	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—psoriasis	0.000486	0.00129	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CARM1—psoriasis	0.000485	0.00602	CbGpPWpGaD
Clodronate—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000485	0.00128	CcSEcCtD
Clodronate—Decreased appetite—Cyclosporine—psoriasis	0.000484	0.00128	CcSEcCtD
Clodronate—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000481	0.00128	CcSEcCtD
Clodronate—Skin disorder—Hydrocortisone—psoriasis	0.000481	0.00128	CcSEcCtD
Clodronate—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000478	0.00127	CcSEcCtD
Clodronate—Renal failure—Methotrexate—psoriasis	0.000475	0.00126	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—ACE—psoriasis	0.000474	0.00588	CbGpPWpGaD
Clodronate—Angioedema—Betamethasone—psoriasis	0.000474	0.00126	CcSEcCtD
Clodronate—Angioedema—Dexamethasone—psoriasis	0.000474	0.00126	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000473	0.00587	CbGpPWpGaD
Clodronate—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000472	0.00125	CcSEcCtD
Clodronate—Anorexia—Hydrocortisone—psoriasis	0.000472	0.00125	CcSEcCtD
Clodronate—Diarrhoea—Mycophenolic acid—psoriasis	0.000471	0.00125	CcSEcCtD
Clodronate—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000469	0.00124	CcSEcCtD
Clodronate—Infection—Triamcinolone—psoriasis	0.000463	0.00123	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.00045	0.00559	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TNF—psoriasis	0.000444	0.00551	CbGpPWpGaD
Clodronate—Urticaria—Cyclosporine—psoriasis	0.000443	0.00117	CcSEcCtD
Clodronate—Abdominal pain—Cyclosporine—psoriasis	0.00044	0.00117	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000439	0.00545	CbGpPWpGaD
Clodronate—Vomiting—Mycophenolic acid—psoriasis	0.000438	0.00116	CcSEcCtD
Clodronate—Dyspepsia—Hydrocortisone—psoriasis	0.000436	0.00116	CcSEcCtD
Clodronate—Rash—Mycophenolic acid—psoriasis	0.000434	0.00115	CcSEcCtD
Clodronate—Dermatitis—Mycophenolic acid—psoriasis	0.000434	0.00115	CcSEcCtD
Clodronate—Urticaria—Mycophenolate mofetil—psoriasis	0.000432	0.00114	CcSEcCtD
Clodronate—Decreased appetite—Hydrocortisone—psoriasis	0.00043	0.00114	CcSEcCtD
Clodronate—Pharyngitis—Methotrexate—psoriasis	0.00043	0.00114	CcSEcCtD
Clodronate—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00043	0.00114	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—psoriasis	0.000428	0.00113	CcSEcCtD
Clodronate—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000427	0.00113	CcSEcCtD
Clodronate—Urethral disorder—Methotrexate—psoriasis	0.000425	0.00113	CcSEcCtD
Clodronate—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000422	0.0226	CbGdCrCtD
Clodronate—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000422	0.0226	CbGdCrCtD
Clodronate—Infection—Betamethasone—psoriasis	0.00042	0.00111	CcSEcCtD
Clodronate—Infection—Dexamethasone—psoriasis	0.00042	0.00111	CcSEcCtD
Clodronate—Anaemia—Prednisone—psoriasis	0.000417	0.00111	CcSEcCtD
Clodronate—Dyspnoea—Triamcinolone—psoriasis	0.000416	0.0011	CcSEcCtD
Clodronate—Angioedema—Prednisone—psoriasis	0.000412	0.00109	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.00041	0.00509	CbGpPWpGaD
Clodronate—Dyspepsia—Triamcinolone—psoriasis	0.00041	0.00109	CcSEcCtD
Clodronate—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.00041	0.022	CbGdCrCtD
Clodronate—Nausea—Mycophenolic acid—psoriasis	0.000409	0.00108	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CARM1—psoriasis	0.000407	0.00505	CbGpPWpGaD
Clodronate—Anorexia—Betamethasone—psoriasis	0.000403	0.00107	CcSEcCtD
Clodronate—Anorexia—Dexamethasone—psoriasis	0.000403	0.00107	CcSEcCtD
Clodronate—Urticaria—Prednisolone—psoriasis	0.000403	0.00107	CcSEcCtD
Clodronate—Pruritus—Cyclosporine—psoriasis	0.000394	0.00105	CcSEcCtD
Clodronate—Urticaria—Hydrocortisone—psoriasis	0.000393	0.00104	CcSEcCtD
Clodronate—Abdominal pain—Hydrocortisone—psoriasis	0.000391	0.00104	CcSEcCtD
Clodronate—Mediastinal disorder—Methotrexate—psoriasis	0.000391	0.00104	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000387	0.00481	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000386	0.00479	CbGpPWpGaD
Clodronate—Pruritus—Mycophenolate mofetil—psoriasis	0.000385	0.00102	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000382	0.00101	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000382	0.00473	CbGpPWpGaD
Clodronate—Diarrhoea—Cyclosporine—psoriasis	0.000381	0.00101	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—LEP—psoriasis	0.000377	0.00468	CbGpPWpGaD
Clodronate—Dyspepsia—Betamethasone—psoriasis	0.000372	0.000987	CcSEcCtD
Clodronate—Dyspepsia—Dexamethasone—psoriasis	0.000372	0.000987	CcSEcCtD
Clodronate—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000372	0.000986	CcSEcCtD
Clodronate—Urticaria—Triamcinolone—psoriasis	0.00037	0.000982	CcSEcCtD
Clodronate—Decreased appetite—Betamethasone—psoriasis	0.000368	0.000975	CcSEcCtD
Clodronate—Decreased appetite—Dexamethasone—psoriasis	0.000368	0.000975	CcSEcCtD
Clodronate—Infection—Prednisone—psoriasis	0.000366	0.00097	CcSEcCtD
Clodronate—Gastrointestinal disorder—Betamethasone—psoriasis	0.000365	0.000968	CcSEcCtD
Clodronate—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000365	0.000968	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL6—psoriasis	0.000358	0.00444	CbGpPWpGaD
Clodronate—Skin disorder—Prednisone—psoriasis	0.000358	0.000949	CcSEcCtD
Clodronate—Vomiting—Cyclosporine—psoriasis	0.000354	0.000939	CcSEcCtD
Clodronate—Rash—Cyclosporine—psoriasis	0.000351	0.000931	CcSEcCtD
Clodronate—Anorexia—Prednisone—psoriasis	0.000351	0.000931	CcSEcCtD
Clodronate—Dermatitis—Cyclosporine—psoriasis	0.000351	0.000931	CcSEcCtD
Clodronate—Pruritus—Hydrocortisone—psoriasis	0.00035	0.000929	CcSEcCtD
Clodronate—Anaemia—Methotrexate—psoriasis	0.000349	0.000925	CcSEcCtD
Clodronate—Vomiting—Mycophenolate mofetil—psoriasis	0.000346	0.000916	CcSEcCtD
Clodronate—Rash—Mycophenolate mofetil—psoriasis	0.000343	0.000909	CcSEcCtD
Clodronate—Dermatitis—Mycophenolate mofetil—psoriasis	0.000342	0.000908	CcSEcCtD
Clodronate—Diarrhoea—Hydrocortisone—psoriasis	0.000339	0.000898	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000337	0.00418	CbGpPWpGaD
Clodronate—Urticaria—Betamethasone—psoriasis	0.000336	0.000891	CcSEcCtD
Clodronate—Urticaria—Dexamethasone—psoriasis	0.000336	0.000891	CcSEcCtD
Clodronate—Abdominal pain—Betamethasone—psoriasis	0.000334	0.000887	CcSEcCtD
Clodronate—Abdominal pain—Dexamethasone—psoriasis	0.000334	0.000887	CcSEcCtD
Clodronate—Nausea—Cyclosporine—psoriasis	0.000331	0.000877	CcSEcCtD
Clodronate—Pruritus—Triamcinolone—psoriasis	0.00033	0.000875	CcSEcCtD
Clodronate—Dyspepsia—Prednisone—psoriasis	0.000324	0.00086	CcSEcCtD
Clodronate—Nausea—Mycophenolate mofetil—psoriasis	0.000323	0.000856	CcSEcCtD
Clodronate—Decreased appetite—Prednisone—psoriasis	0.00032	0.000849	CcSEcCtD
Clodronate—Rash—Prednisolone—psoriasis	0.00032	0.000848	CcSEcCtD
Clodronate—Dermatitis—Prednisolone—psoriasis	0.000319	0.000847	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000319	0.000846	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000318	0.0171	CbGdCrCtD
Clodronate—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000318	0.0171	CbGdCrCtD
Clodronate—SLC25A4—Metabolism—CARM1—psoriasis	0.000317	0.00394	CbGpPWpGaD
Clodronate—Vomiting—Hydrocortisone—psoriasis	0.000315	0.000835	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000313	0.00389	CbGpPWpGaD
Clodronate—Rash—Hydrocortisone—psoriasis	0.000312	0.000828	CcSEcCtD
Clodronate—Dermatitis—Hydrocortisone—psoriasis	0.000312	0.000827	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000311	0.0167	CbGdCrCtD
Clodronate—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	0.000306	0.0038	CbGpPWpGaD
Clodronate—Infection—Methotrexate—psoriasis	0.000306	0.000811	CcSEcCtD
Clodronate—Nausea—Prednisolone—psoriasis	0.000301	0.000798	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.0003	0.00372	CbGpPWpGaD
Clodronate—Pruritus—Betamethasone—psoriasis	0.000299	0.000794	CcSEcCtD
Clodronate—Pruritus—Dexamethasone—psoriasis	0.000299	0.000794	CcSEcCtD
Clodronate—Skin disorder—Methotrexate—psoriasis	0.000299	0.000793	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CAT—psoriasis	0.000298	0.0037	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HLA-A—psoriasis	0.000297	0.00368	CbGpPWpGaD
Clodronate—Vomiting—Triamcinolone—psoriasis	0.000296	0.000786	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—LEP—psoriasis	0.000294	0.00365	CbGpPWpGaD
Clodronate—Nausea—Hydrocortisone—psoriasis	0.000294	0.00078	CcSEcCtD
Clodronate—Rash—Triamcinolone—psoriasis	0.000294	0.000779	CcSEcCtD
Clodronate—Dermatitis—Triamcinolone—psoriasis	0.000294	0.000779	CcSEcCtD
Clodronate—Anorexia—Methotrexate—psoriasis	0.000293	0.000778	CcSEcCtD
Clodronate—Urticaria—Prednisone—psoriasis	0.000293	0.000776	CcSEcCtD
Clodronate—Abdominal pain—Prednisone—psoriasis	0.000291	0.000772	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000291	0.00361	CbGpPWpGaD
Clodronate—Diarrhoea—Betamethasone—psoriasis	0.000289	0.000767	CcSEcCtD
Clodronate—Diarrhoea—Dexamethasone—psoriasis	0.000289	0.000767	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	0.000282	0.00349	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL4—psoriasis	0.00028	0.00348	CbGpPWpGaD
Clodronate—Nausea—Triamcinolone—psoriasis	0.000277	0.000734	CcSEcCtD
Clodronate—SLC25A5—Disease—APOE—psoriasis	0.000277	0.00344	CbGpPWpGaD
Clodronate—Dyspnoea—Methotrexate—psoriasis	0.000275	0.000728	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000272	0.00337	CbGpPWpGaD
Clodronate—Dyspepsia—Methotrexate—psoriasis	0.000271	0.000719	CcSEcCtD
Clodronate—Vomiting—Dexamethasone—psoriasis	0.000269	0.000713	CcSEcCtD
Clodronate—Vomiting—Betamethasone—psoriasis	0.000269	0.000713	CcSEcCtD
Clodronate—Decreased appetite—Methotrexate—psoriasis	0.000268	0.00071	CcSEcCtD
Clodronate—Rash—Betamethasone—psoriasis	0.000267	0.000707	CcSEcCtD
Clodronate—Rash—Dexamethasone—psoriasis	0.000267	0.000707	CcSEcCtD
Clodronate—Dermatitis—Dexamethasone—psoriasis	0.000266	0.000707	CcSEcCtD
Clodronate—Dermatitis—Betamethasone—psoriasis	0.000266	0.000707	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—psoriasis	0.000266	0.000705	CcSEcCtD
Clodronate—Pruritus—Prednisone—psoriasis	0.000261	0.000691	CcSEcCtD
Clodronate—SLC25A5—Disease—NOS2—psoriasis	0.000258	0.0032	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000256	0.00317	CbGpPWpGaD
Clodronate—Diarrhoea—Prednisone—psoriasis	0.000252	0.000668	CcSEcCtD
Clodronate—Nausea—Betamethasone—psoriasis	0.000251	0.000666	CcSEcCtD
Clodronate—Nausea—Dexamethasone—psoriasis	0.000251	0.000666	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CXCL8—psoriasis	0.000251	0.00311	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CAT—psoriasis	0.00025	0.0031	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HLA-A—psoriasis	0.000249	0.00308	CbGpPWpGaD
Clodronate—Urticaria—Methotrexate—psoriasis	0.000245	0.000649	CcSEcCtD
Clodronate—Abdominal pain—Methotrexate—psoriasis	0.000243	0.000645	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—LEP—psoriasis	0.000237	0.00294	CbGpPWpGaD
Clodronate—Vomiting—Prednisone—psoriasis	0.000234	0.000621	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000233	0.00289	CbGpPWpGaD
Clodronate—Rash—Prednisone—psoriasis	0.000232	0.000616	CcSEcCtD
Clodronate—Dermatitis—Prednisone—psoriasis	0.000232	0.000615	CcSEcCtD
Clodronate—SLC25A6—Disease—APOE—psoriasis	0.000232	0.00288	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—APOE—psoriasis	0.000232	0.00288	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	0.000223	0.00276	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—NOS2—psoriasis	0.000221	0.00274	CbGpPWpGaD
Clodronate—Nausea—Prednisone—psoriasis	0.000219	0.00058	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.000218	0.0027	CbGpPWpGaD
Clodronate—Pruritus—Methotrexate—psoriasis	0.000218	0.000578	CcSEcCtD
Clodronate—SLC25A6—Disease—NOS2—psoriasis	0.000216	0.00268	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD4—psoriasis	0.000215	0.00267	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	0.000214	0.00266	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TYK2—psoriasis	0.000211	0.00262	CbGpPWpGaD
Clodronate—Diarrhoea—Methotrexate—psoriasis	0.000211	0.000559	CcSEcCtD
Clodronate—SLC25A5—Metabolism—PPARG—psoriasis	0.000202	0.00251	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—psoriasis	0.000196	0.000519	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—CXCL8—psoriasis	0.000196	0.00243	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CAT—psoriasis	0.000195	0.00242	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—APOE—psoriasis	0.000194	0.00241	CbGpPWpGaD
Clodronate—Rash—Methotrexate—psoriasis	0.000194	0.000515	CcSEcCtD
Clodronate—SLC25A4—Disease—HLA-A—psoriasis	0.000194	0.00241	CbGpPWpGaD
Clodronate—Dermatitis—Methotrexate—psoriasis	0.000194	0.000514	CcSEcCtD
Clodronate—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000192	0.0103	CbGdCrCtD
Clodronate—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000192	0.0103	CbGdCrCtD
Clodronate—SLC25A5—Disease—CD4—psoriasis	0.000191	0.00237	CbGpPWpGaD
Clodronate—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000188	0.0101	CbGdCrCtD
Clodronate—Nausea—Methotrexate—psoriasis	0.000183	0.000485	CcSEcCtD
Clodronate—SLC25A4—Disease—APOE—psoriasis	0.000181	0.00225	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000179	0.00222	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	0.000178	0.00221	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TYK2—psoriasis	0.000177	0.0022	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IFNG—psoriasis	0.000169	0.0021	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PPARG—psoriasis	0.000169	0.0021	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NOS2—psoriasis	0.000169	0.00209	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—psoriasis	0.00016	0.00199	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	0.000158	0.00195	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—APOE—psoriasis	0.000152	0.00188	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NDUFA5—psoriasis	0.000151	0.00188	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.00015	0.00186	CbGpPWpGaD
Clodronate—SLC25A5—Disease—STAT3—psoriasis	0.000148	0.00184	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000141	0.00175	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	0.000139	0.00172	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TYK2—psoriasis	0.000138	0.00172	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PPARG—psoriasis	0.000132	0.00164	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP2S1—psoriasis	0.000129	0.00159	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—psoriasis	0.000125	0.00155	CbGpPWpGaD
Clodronate—SLC25A6—Disease—STAT3—psoriasis	0.000124	0.00154	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	0.000112	0.00139	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—psoriasis	0.00011	0.00136	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—psoriasis	0.000103	0.00128	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.96e-05	0.00124	CbGpPWpGaD
Clodronate—SLC25A4—Disease—STAT3—psoriasis	9.68e-05	0.0012	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—psoriasis	9.67e-05	0.0012	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	9.59e-05	0.00119	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—psoriasis	8.85e-05	0.0011	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.71e-05	0.00108	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—psoriasis	8.66e-05	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.46e-05	0.000926	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—psoriasis	6.76e-05	0.000839	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.74e-05	0.000836	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.58e-05	0.000816	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CARM1—psoriasis	6.28e-05	0.000779	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.87e-05	0.000728	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CAT—psoriasis	3.86e-05	0.000479	CbGpPWpGaD
Clodronate—PTGS2—Disease—HLA-A—psoriasis	3.84e-05	0.000476	CbGpPWpGaD
Clodronate—PTGS2—Disease—APOE—psoriasis	3.58e-05	0.000444	CbGpPWpGaD
Clodronate—PTGS2—Disease—NOS2—psoriasis	3.34e-05	0.000414	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—APOE—psoriasis	3e-05	0.000372	CbGpPWpGaD
Clodronate—PTGS2—Disease—TYK2—psoriasis	2.73e-05	0.000339	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARG—psoriasis	2.61e-05	0.000324	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—psoriasis	2.47e-05	0.000307	CbGpPWpGaD
Clodronate—PTGS2—Disease—STAT3—psoriasis	1.91e-05	0.000237	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—psoriasis	1.34e-05	0.000166	CbGpPWpGaD
